Advanz Pharma Corp. Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Advanz Pharma Corp. Limited - overview
Established
2003
Location
London, -, UK
Primary Industry
Pharmaceuticals
About
Founded in 2003, and based in London, UK, Advanz Pharma Corp. Limited, a. k. a.
Advanz Pharma operates as a pharmaceutical company. It was formed via the merger between AMCO and Concordia International Corp. As of August 2025, the company has a commercial presence in over 20 countries and sales in more than 90 countries worldwide. The current Chief Executive Officer is Steffen Wagner, who joined the company in April 2022.
In February 2024, Ontario Teachers' Pension Plan and Nordic Capital agreed to invest in Advanz Pharma Corp. Limited. Advanz Pharma researches, develops, and retails medications by partnering with other biopharmaceutical and pharmaceutical development companies. As of August 2025, the company offers a portfolio of over 180 specialty medicines, including treatments in endocrinology, ophthalmology, urology, anti-infectives, pain management, CNS disorders, oncology, hematology, cardiology, and intensive care.
The firm is also expanding into biosimilars and specialty generics, partnering with biopharma innovators to launch new products.
Current Investors
Nordic Capital
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.advanzpharma.com
Verticals
Manufacturing
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Advanz Pharma Corp. Limited - timeline of key events
Advanz Pharma Corp. Limited - financials
| Fiscal Year Ended | Mar 31, 2011 | Mar 31, 2012 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 17,246,901 | 11,810,030 | 54,567,853 | 33,224,468 | 51,477,522 | 56,728,038 | 95,312,659 | 51,870,097 | 51,066,376 | 69,132,880 | 48,766,404 | 64,089,028 | - | - | - |
| % Revenue Growth (YoY) | - | (31.5%) | - | - | 54.9% | 10.2% | 68.0% | (45.6%) | (1.5%) | 35.4% | (29.5%) | 31.4% | - | - | - |
| EBITDA (USD) | 4,589,534 | 903,862 | 4,118,203 | 14,008,535 | 25,433,575 | 28,753,013 | 50,215,630 | 9,722,843 | 4,728,804 | 18,420,652 | 2,009,025 | 58,123 | - | - | - |
| Operating Income (USD) | 4,549,458 | 824,466 | 3,995,711 | 13,752,845 | 24,837,885 | 28,208,292 | 49,620,543 | 8,943,316 | 4,032,636 | 17,657,498 | 1,360,229 | (745,510) | - | - | - |
| Operating Margin | 26.4% | 7.0% | 7.3% | 41.4% | 48.2% | 49.7% | 52.1% | 17.2% | 7.9% | 25.5% | 2.8% | (1.2%) | - | - | - |
| % EBITDA Margin | 26.6% | 7.7% | 7.5% | 42.2% | 49.4% | 50.7% | 52.7% | 18.7% | 9.3% | 26.6% | 4.1% | 0.1% | - | - | - |
| NET Income (USD) | 3,321,562 | 883,633 | 3,509,944 | 11,529,103 | 19,047,095 | 22,713,979 | 38,391,581 | 6,247,813 | 3,036,221 | 17,264,052 | (13,329,508) | (568,523) | - | - | - |
| % Net Margin | 19.3% | 7.5% | 6.4% | 34.7% | 37.0% | 40.0% | 40.3% | 12.0% | 5.9% | 25.0% | (27.3%) | (0.9%) | - | - | - |
Advanz Pharma Corp. Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Sanofi's anti-infective portfolio | - | ||||||||
| Add-on | Completed | Intercept Pharmaceuticals, Inc.'s Business in Europe, Canada, and non U.S. | - | ||||||||
| Buyout | Completed | Advanz Pharma Corp. Limited | - |
Displaying 1 - 3 of 3
Advanz Pharma Corp. Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.